Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation

Takashi Ikeda, Keita Mori, Koji Kawamura, Takehiko Mori, Shotaro Hagiwara, Yasunori Ueda, Kaoru Kahata, Naoyuki Uchida, Nobuhiro Tsukada, Satoshi Murakami, Masahide Yamamoto, Tsutomu Takahashi, Tatsuo Ichinohe, Makoto Onizuka, Yoshiko Atsuta, Yoshinobu Kanda, Shinichiro Okamoto, Kazutaka Sunami, Hiroyuki Takamatsu

Research output: Contribution to journalArticle

Abstract

Allogeneic stem cell transplantation (allo-SCT) offers a clinical option to young patients with multiple myeloma (MM) relapsing/progressing after autologous SCT (ASCT); however, this claim remains debatable. Thus, in this retrospective study, we analyzed 526 patients with MM who underwent SCT for MM relapsing/progressing after the prior ASCT using the registry data of the Japan Society for Hematopoietic Cell Transplantation (2001-2015) and compared overall survival (OS) between allo-SCT (n = 192) and autologous stem cell retransplantation groups (ReASCT; n = 334) based on risk factor points. Significant adverse factors for OS in all patients were (1) male sex, (2) less than partial response to SCT, (3) performance status of 2 to 4, and (4) short duration from the prior ASCT. We scored factor 2 as 1 point, factor 3 as 2 points, and factor 4 as 0, 1, or 2 points for more than 30, 9 to 30, or less than 9 months, respectively. We categorized patients into three risk subgroups based on their total points (0, 1-3, and 4-5 points), indicating the usefulness of this scoring system for prognosis prediction and treatment selection. Subgroup comparison revealed OS after ReASCT to be higher than that after allo-SCT in the intermediate-risk subgroup comprising the largest population (28.2% vs 21.5%, P <.004). We observed no significant advantages of allo-SCT over ReASCT in the low- and high-risk subgroups. These findings suggest that ReASCT is more advantageous than allo-SCT in many patients with MM relapsing/progressing after the prior ASCT. However, long-term survival patients were noted only in the allo-SCT group, and allo-SCT could exhibit clinical efficacy, particularly in the low-risk group. While further examination is warranted, allo-SCT could be a potential tool for a specific population with MM relapsing/progressing after the prior ASCT.

Original languageEnglish
JournalHematological Oncology
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Salvage Therapy
Stem Cell Transplantation
Multiple Myeloma
Survival
Cell Transplantation
Population
Registries
Japan
Stem Cells
Retrospective Studies

Keywords

  • humans
  • multiple myeloma
  • prognosis
  • stem cell transplantation
  • treatment outcome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. / Ikeda, Takashi; Mori, Keita; Kawamura, Koji; Mori, Takehiko; Hagiwara, Shotaro; Ueda, Yasunori; Kahata, Kaoru; Uchida, Naoyuki; Tsukada, Nobuhiro; Murakami, Satoshi; Yamamoto, Masahide; Takahashi, Tsutomu; Ichinohe, Tatsuo; Onizuka, Makoto; Atsuta, Yoshiko; Kanda, Yoshinobu; Okamoto, Shinichiro; Sunami, Kazutaka; Takamatsu, Hiroyuki.

In: Hematological Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Ikeda, T, Mori, K, Kawamura, K, Mori, T, Hagiwara, S, Ueda, Y, Kahata, K, Uchida, N, Tsukada, N, Murakami, S, Yamamoto, M, Takahashi, T, Ichinohe, T, Onizuka, M, Atsuta, Y, Kanda, Y, Okamoto, S, Sunami, K & Takamatsu, H 2019, 'Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation', Hematological Oncology. https://doi.org/10.1002/hon.2688
Ikeda, Takashi ; Mori, Keita ; Kawamura, Koji ; Mori, Takehiko ; Hagiwara, Shotaro ; Ueda, Yasunori ; Kahata, Kaoru ; Uchida, Naoyuki ; Tsukada, Nobuhiro ; Murakami, Satoshi ; Yamamoto, Masahide ; Takahashi, Tsutomu ; Ichinohe, Tatsuo ; Onizuka, Makoto ; Atsuta, Yoshiko ; Kanda, Yoshinobu ; Okamoto, Shinichiro ; Sunami, Kazutaka ; Takamatsu, Hiroyuki. / Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. In: Hematological Oncology. 2019.
@article{e82b63bbed6142a69481ecf7872e9020,
title = "Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation",
abstract = "Allogeneic stem cell transplantation (allo-SCT) offers a clinical option to young patients with multiple myeloma (MM) relapsing/progressing after autologous SCT (ASCT); however, this claim remains debatable. Thus, in this retrospective study, we analyzed 526 patients with MM who underwent SCT for MM relapsing/progressing after the prior ASCT using the registry data of the Japan Society for Hematopoietic Cell Transplantation (2001-2015) and compared overall survival (OS) between allo-SCT (n = 192) and autologous stem cell retransplantation groups (ReASCT; n = 334) based on risk factor points. Significant adverse factors for OS in all patients were (1) male sex, (2) less than partial response to SCT, (3) performance status of 2 to 4, and (4) short duration from the prior ASCT. We scored factor 2 as 1 point, factor 3 as 2 points, and factor 4 as 0, 1, or 2 points for more than 30, 9 to 30, or less than 9 months, respectively. We categorized patients into three risk subgroups based on their total points (0, 1-3, and 4-5 points), indicating the usefulness of this scoring system for prognosis prediction and treatment selection. Subgroup comparison revealed OS after ReASCT to be higher than that after allo-SCT in the intermediate-risk subgroup comprising the largest population (28.2{\%} vs 21.5{\%}, P <.004). We observed no significant advantages of allo-SCT over ReASCT in the low- and high-risk subgroups. These findings suggest that ReASCT is more advantageous than allo-SCT in many patients with MM relapsing/progressing after the prior ASCT. However, long-term survival patients were noted only in the allo-SCT group, and allo-SCT could exhibit clinical efficacy, particularly in the low-risk group. While further examination is warranted, allo-SCT could be a potential tool for a specific population with MM relapsing/progressing after the prior ASCT.",
keywords = "humans, multiple myeloma, prognosis, stem cell transplantation, treatment outcome",
author = "Takashi Ikeda and Keita Mori and Koji Kawamura and Takehiko Mori and Shotaro Hagiwara and Yasunori Ueda and Kaoru Kahata and Naoyuki Uchida and Nobuhiro Tsukada and Satoshi Murakami and Masahide Yamamoto and Tsutomu Takahashi and Tatsuo Ichinohe and Makoto Onizuka and Yoshiko Atsuta and Yoshinobu Kanda and Shinichiro Okamoto and Kazutaka Sunami and Hiroyuki Takamatsu",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hon.2688",
language = "English",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation

AU - Ikeda, Takashi

AU - Mori, Keita

AU - Kawamura, Koji

AU - Mori, Takehiko

AU - Hagiwara, Shotaro

AU - Ueda, Yasunori

AU - Kahata, Kaoru

AU - Uchida, Naoyuki

AU - Tsukada, Nobuhiro

AU - Murakami, Satoshi

AU - Yamamoto, Masahide

AU - Takahashi, Tsutomu

AU - Ichinohe, Tatsuo

AU - Onizuka, Makoto

AU - Atsuta, Yoshiko

AU - Kanda, Yoshinobu

AU - Okamoto, Shinichiro

AU - Sunami, Kazutaka

AU - Takamatsu, Hiroyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Allogeneic stem cell transplantation (allo-SCT) offers a clinical option to young patients with multiple myeloma (MM) relapsing/progressing after autologous SCT (ASCT); however, this claim remains debatable. Thus, in this retrospective study, we analyzed 526 patients with MM who underwent SCT for MM relapsing/progressing after the prior ASCT using the registry data of the Japan Society for Hematopoietic Cell Transplantation (2001-2015) and compared overall survival (OS) between allo-SCT (n = 192) and autologous stem cell retransplantation groups (ReASCT; n = 334) based on risk factor points. Significant adverse factors for OS in all patients were (1) male sex, (2) less than partial response to SCT, (3) performance status of 2 to 4, and (4) short duration from the prior ASCT. We scored factor 2 as 1 point, factor 3 as 2 points, and factor 4 as 0, 1, or 2 points for more than 30, 9 to 30, or less than 9 months, respectively. We categorized patients into three risk subgroups based on their total points (0, 1-3, and 4-5 points), indicating the usefulness of this scoring system for prognosis prediction and treatment selection. Subgroup comparison revealed OS after ReASCT to be higher than that after allo-SCT in the intermediate-risk subgroup comprising the largest population (28.2% vs 21.5%, P <.004). We observed no significant advantages of allo-SCT over ReASCT in the low- and high-risk subgroups. These findings suggest that ReASCT is more advantageous than allo-SCT in many patients with MM relapsing/progressing after the prior ASCT. However, long-term survival patients were noted only in the allo-SCT group, and allo-SCT could exhibit clinical efficacy, particularly in the low-risk group. While further examination is warranted, allo-SCT could be a potential tool for a specific population with MM relapsing/progressing after the prior ASCT.

AB - Allogeneic stem cell transplantation (allo-SCT) offers a clinical option to young patients with multiple myeloma (MM) relapsing/progressing after autologous SCT (ASCT); however, this claim remains debatable. Thus, in this retrospective study, we analyzed 526 patients with MM who underwent SCT for MM relapsing/progressing after the prior ASCT using the registry data of the Japan Society for Hematopoietic Cell Transplantation (2001-2015) and compared overall survival (OS) between allo-SCT (n = 192) and autologous stem cell retransplantation groups (ReASCT; n = 334) based on risk factor points. Significant adverse factors for OS in all patients were (1) male sex, (2) less than partial response to SCT, (3) performance status of 2 to 4, and (4) short duration from the prior ASCT. We scored factor 2 as 1 point, factor 3 as 2 points, and factor 4 as 0, 1, or 2 points for more than 30, 9 to 30, or less than 9 months, respectively. We categorized patients into three risk subgroups based on their total points (0, 1-3, and 4-5 points), indicating the usefulness of this scoring system for prognosis prediction and treatment selection. Subgroup comparison revealed OS after ReASCT to be higher than that after allo-SCT in the intermediate-risk subgroup comprising the largest population (28.2% vs 21.5%, P <.004). We observed no significant advantages of allo-SCT over ReASCT in the low- and high-risk subgroups. These findings suggest that ReASCT is more advantageous than allo-SCT in many patients with MM relapsing/progressing after the prior ASCT. However, long-term survival patients were noted only in the allo-SCT group, and allo-SCT could exhibit clinical efficacy, particularly in the low-risk group. While further examination is warranted, allo-SCT could be a potential tool for a specific population with MM relapsing/progressing after the prior ASCT.

KW - humans

KW - multiple myeloma

KW - prognosis

KW - stem cell transplantation

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85075477369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075477369&partnerID=8YFLogxK

U2 - 10.1002/hon.2688

DO - 10.1002/hon.2688

M3 - Article

C2 - 31674032

AN - SCOPUS:85075477369

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

ER -